{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:09:29Z","timestamp":1790262569485,"version":"4.1.0"},"reference-count":11,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The antibacterial activity of DQ-113, formerly D61-1113, was compared with those of antibacterial agents currently available. MICs at which 90% of the isolates tested are inhibited (MIC\n            <jats:sub>90<\/jats:sub>\n            s) of DQ-113 against clinical isolates of methicillin-susceptible and -resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            and methicillin-susceptible and -resistant coagulase-negative staphylococci were 0.03, 0.008, 0.03, and 0.06 \u03bcg\/ml, respectively. Moreover, DQ-113 showed the most potent activity against ofloxacin-resistant and methicillin-resistant\n            <jats:italic>S. aureus<\/jats:italic>\n            , with a MIC\n            <jats:sub>90<\/jats:sub>\n            of 0.25\u03bcg\/ml. DQ-113 inhibited the growth of all strains of\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            , including penicillin-resistant strains, and\n            <jats:italic>Streptococcus pyogenes<\/jats:italic>\n            at 0.06 \u03bcg\/ml, and DQ-113 was more active than the other quinolones tested against\n            <jats:italic>Enterococcus faecalis<\/jats:italic>\n            and\n            <jats:italic>Enterococcus faecium<\/jats:italic>\n            with MIC90s of 0.25 and 2 \u03bcg\/ml, respectively. Against vancomycin-resistant enterococci, DQ-113 showed the highest activity among the reference compounds, with a MIC range from 0.25 to 2 \u03bcg\/ml. DQ-113 also showed a potent activity against\n            <jats:italic>Haemophilus influenzae<\/jats:italic>\n            , including ampicillin-resistant strains (MIC90, 0.015 \u03bcg\/ml), and\n            <jats:italic>Moraxella catarrhalis<\/jats:italic>\n            (MIC90, 0.03 \u03bcg\/ml). The activity of DQ-113 was roughly comparable to that of levofloxacin against all species of\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            . The MICs of DQ-113 against ofloxacin-susceptible\n            <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n            ranged from 0.25 to 2 \u03bcg\/ml, which were four times higher than those of ciprofloxacin. From these results, DQ-113 showed the most potent activity against gram-positive pathogens among antibacterial agents tested.\n          <\/jats:p>","DOI":"10.1128\/aac.46.3.904-908.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:56:57Z","timestamp":1027763817000},"page":"904-908","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":16,"title":["In Vitro Antibacterial Activities of DQ-113, a Potent Quinolone, against Clinical Isolates"],"prefix":"10.1128","volume":"46","author":[{"given":"Mayumi","family":"Tanaka","sequence":"first","affiliation":[{"name":"New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Chiba","sequence":"additional","affiliation":[{"name":"New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomi","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Akasaka","sequence":"additional","affiliation":[{"name":"New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Takemura","sequence":"additional","affiliation":[{"name":"New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Sato","sequence":"additional","affiliation":[{"name":"New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0749-0704(05)70397-3","volume":"14","year":"1998","unstructured":"Cunha, B. A. 1998. Antibiotic resistance. Control strategies. Crit. Care Clin.14:309-327.","journal-title":"Crit. Care Clin."},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1007\/BF01793575","volume":"22","year":"1994","unstructured":"Dalhoff, A. 1994. Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance. Infection22(Suppl.):S111-S121.","journal-title":"Infection"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050379"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.1.3"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.5.716"},{"key":"e_1_3_1_7_2","unstructured":"National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.1.128"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.suppl_1.37"},{"key":"e_1_3_1_10_2","first-page":"1","volume":"44","year":"1999","unstructured":"Witte, W. 1999. Antibiotic resistance in Gram-positive bacteria: epidemiological aspects. J. Antimicrob. Chemother.44(Suppl. A):1-9.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/11.Supplement_5.S960"},{"key":"e_1_3_1_12_2","first-page":"387","volume":"53","year":"2000","unstructured":"Yamaguchi, K., S. Miyazaki, F. Kashitani, M. Iwata, and Levofloxacin Surveillance Group. 2000. Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Jpn. J. Antibiot.53:387-408.","journal-title":"Jpn. J. Antibiot."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.3.904-908.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.3.904-908.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:40:27Z","timestamp":1645465227000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.3.904-908.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1128\/AAC.46.3.904-908.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.3.904-908.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]},"assertion":[{"value":"2001-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-11-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}